U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365332) titled 'An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)' on Jan. 22.
Brief Summary: This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Pulmonary Arterial Hypertension
Intervention:
DRUG: IKT-001
IKT-001 tablets for PO administration
DRUG: Placebo
Placebo to IKT-001 tablets for PO administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Inhibikase Therapeutics
Published by HT Di...